This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

Introduction Linezolid can cause serious adverse effects including thrombocytopenia and
anemia. Here, we focus specifically on linezolid-related hematological toxicity in adult …

Tuberculosis (TB) is currently the second deadliest infectious disease. Existing
antitubercular therapies are long, complex, and have severe side effects that result in low …

Background Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only
one-third of persons start treatment, and outcomes are often inadequate. Several trials …

Introduction Tuberculosis remains a significant concern in global public health due to its
intricate biology and propensity for develo** antibiotic resistance. Discovering new drugs …

Operational handbook on tuberculosis. Module 4: Treatment of drug-resistant tuberculosis
treatment, is a derivative product arising from the guideline on the same topic. This …

Linezolid is a drug with proven human antitubercular activity whose use is limited to highly
drug-resistant patients because of its toxicity. This toxicity is related to its mechanism of …

Tuberculosis (TB) remains a significant global health challenge, with “multidrug-resistant
(MDR-TB) and extensively drug-resistant (XDR-TB) strains” posing severe threats to …

Introduction Linezolid is recommended in treatment regimens for rifampin-or multi-drug-
resistant tuberculosis. However, considerable pharmacokinetic variability exists, and long …

Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to
heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR …